FOLH1 and Familial prostate cancer: Our recent work also demonstrated that the 89Zr radiolabeled YS5 (89Zr-DFO-YS5) can detect prostate cancer in vivo in both PSMA positive and PSMA negative mCRPC cell line xenograft (CDX) models and patient derived xenograft (PDX) models of both the adenocarcinoma and neuroendocrine subtypes [21], and a first-in-human study of this novel PET agent is ongoing in mCRPC patients (NCT05245006).